Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC

David Blum, Dieter Koeberle, Karin Ribi, Shu-Fang Hsu Schmitz, Urs Utiger, Dirk Klingbiel, Florian Strasser, David Blum, Dieter Koeberle, Karin Ribi, Shu-Fang Hsu Schmitz, Urs Utiger, Dirk Klingbiel, Florian Strasser

Abstract

Background: In patients with advanced, incurable cancer, anticancer treatment may be used to alleviate cancer-related symptoms, but monitoring of them in daily practice is rarely done. We aim to test the effectiveness of a real-time symptom and syndrome assessment using the E-MOSAIC software installed in handheld computer generating a longitudinal monitoring sheet (LoMoS) provided to the oncologists in a phase III setting.

Methods: In this prospective multicentre cluster randomized phase-III trial patients with any incurable solid tumor and having defined cancer related symptoms, who receive new outpatient chemotherapy in palliative intention (expected tumor-size response rate ≤20%) are eligible. Immediately before the weekly visit to oncologists, all patients complete with nurse assistance the E-MOSAIC Assessment: Edmonton Symptom Assessment Scale, ≤3 additional symptoms, estimated nutritional intake, body weight, Karnofsky and medications for pain and cachexia. Experienced oncologists will be randomized to receive the LoMoS or not. To minimize contamination, LoMoS are removed from the medical charts after visits. Primary endpoint is the difference in global quality of life (items 29 & 30 of EORTC-QlQ-C30) between baseline and last study visit at week 6, with a 10 point between-arm difference considered to be clinically relevant. 20 clusters (=oncologists) per treatment arm with 4-8 patients each are aimed for to achieve a significance level of 5% and a power of 80% in a mixed model approach. Selected co- variables are included in the model for adjustment. Secondary endpoints include patient-perceived patient-physician communication symptom burden over time, and oncologists' symptom management performance (predefined thresholds of symptoms compared to oncologists' pharmacological, diagnostic or counselling actions [structured chart review]).

Discussion: This trial will contribute to the research question, whether structured, longitudinal monitoring of patients' multidimensional symptoms, indicators for symptom management, and clinical benefit outcomes can influence patients' quality of life and symptom distress, in a setting of routine oncology practice.

Trial registration: Current Controlled Trials NCT00477919.

Figures

Figure 1
Figure 1
Screenshot from Palm as illustration.
Figure 2
Figure 2
Longitudinal monitoring Sheet: LoMoS.
Figure 3
Figure 3
Randomization with intervention.
Figure 4
Figure 4
Study flow with visits and forms.

References

    1. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol. 2001;19(11230467):1266–1274.
    1. Michael M, Hedley D, Oza A, Feld R, Pintilie M, Goel R, Maroun J, Jolivet J, Fields A, Lee IM. et al.The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. Clin Colorectal Cancer. 2002;2(2):93–101. doi: 10.3816/CCC.2002.n.015.
    1. Michael M, Tannock IF. Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ. 1998;158(9676550):1727–1734.
    1. Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593–a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(11304763):2114–2122.
    1. Passik SD, Kirsh KL. The importance of quality-of-life endpoints in clinical trials to the practicing oncologist. Hematol Oncol Clin North Am. 2000;14(10949778):877–886.
    1. Gough IR, Dalgleish LI. What value is given to quality of life assessment by health professionals considering response to palliative chemotherapy for advanced cancer? Cancer. 1991;68(1710947):220–225.
    1. Morris J, Perez D, McNoe B. The use of quality of life data in clinical practice. Qual Life Res. 1998;7(9481154):85–91.
    1. Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Role of health-related quality of life in palliative chemotherapy treatment decisions. J Clin Oncol. 2002;20(11844830):1056–1062.
    1. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D’Haese S, Zurlo A. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials–does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol. 2003;21(12972527):3502–3511.
    1. Buchanan DR, O’Mara AM, Kelaghan JW, Minasian LM. Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported Community Clinical Oncology Program. J Clin Oncol. 2005;23(3):591–598.
    1. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI. et al.Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007;25(34):5374–5380. doi: 10.1200/JCO.2007.11.2243.
    1. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006;83(6):1345–1350.
    1. Velikova G, Wright P, Smith AB, Stark D, Perren T, Brown J, Selby P. Self-reported quality of life of individual cancer patients: concordance of results with disease course and medical records. J Clin Oncol. 2001;19(11283140):2064–2073.
    1. Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288(12479768):3027–3034.
    1. Fisch MJ, Titzer ML, Kristeller JL, Shen J, Loehrer PJ, Jung S-H, Passik SD, Einhorn LH. Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being–a Hoosier Oncology Group Study. J Clin Oncol. 2003;21(12860955):2754–2759.
    1. Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M. Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer. 2006;42(16624553):1159–1166.
    1. Shepherd HL, Tattersall MH, Butow PN. Physician-identified factors affecting patient participation in reaching treatment decisions. J Clin Oncol. 2008;26(10):1724–1731. doi: 10.1200/JCO.2007.13.5566.
    1. Deveugele M, Derese A, van den Brink-Muinen A, Bensing J, De Maeseneer J. Consultation length in general practice: cross sectional study in six European countries. BMJ (Clinical research ed) 2002;325(7362):472. doi: 10.1136/bmj.325.7362.472.
    1. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P. et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(9196156):2403–2413.
    1. Berry DL, Blumenstein BA, Halpenny B, Wolpin S, Fann JR, Austin-Seymour M, Bush N, Karras BT, Lober WB, McCorkle R. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol. 2011;29(8):1029–1035. doi: 10.1200/JCO.2010.30.3909.
    1. Weissman DE, Meier DE. Identifying patients in need of a palliative care assessment in the hospital setting: a consensus report from the Center to Advance Palliative Care. J Palliat Med. 2011;14(1):17–23. doi: 10.1089/jpm.2010.0347.
    1. Abernethy AP, Zafar SY, Uronis H, Wheeler JL, Coan A, Rowe K, Shelby RA, Fowler R, Herndon JE 2nd. Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. J Pain Symptom Manage. 2010;40(4):545–558. doi: 10.1016/j.jpainsymman.2010.01.017.
    1. Shirai Y, Fujimori M, Ogawa A, Yamada Y, Nishiwaki Y, Ohtsu A, Uchitomi Y. Patients’ perception of the usefulness of a question prompt sheet for advanced cancer patients when deciding the initial treatment: a randomized, controlled trial. Psychooncology. 2012;21(7):706–713. doi: 10.1002/pon.1955.
    1. Velikova G, Brown JM, Smith AB, Selby PJ. Computer-based quality of life questionnaires may contribute to doctor-patient interactions in oncology. Br J Cancer. 2002;86(11857011):51–59.
    1. Stromgren AS, Goldschmidt D, Groenvold M, Petersen MA, Jensen PT, Pedersen L, Hoermann L, Helleberg C, Sjogren P. Self-assessment in cancer patients referred to palliative care: a study of feasibility and symptom epidemiology. Cancer. 2002;94(11900236):512–520.
    1. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(1714502):6–9.
    1. Vignaroli E, Pace EA, Willey J, Palmer JL, Zhang T, Bruera E. The Edmonton Symptom Assessment System as a screening tool for depression and anxiety. J Palliat Med. 2006;9(16629559):296–303.
    1. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manag. 2007;34(1):94–104. doi: 10.1016/j.jpainsymman.2006.10.015.
    1. Murray DM, Varnell SP, Blitstein JL. Design and analysis of group-randomized trials: a review of recent methodological developments. Am J Public Health. 2004;94(3):423–432. doi: 10.2105/AJPH.94.3.423.
    1. Fayers PM. Evaluating the effectiveness of using PROs in clinical practice: a role for cluster-randomised trials. Qual Life Res. 2008;17(10):1315–1321. doi: 10.1007/s11136-008-9391-9.
    1. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451–1454. doi: 10.1046/j.1532-5415.2003.51465.x.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(8433390):365–376.
    1. Fogarty LA, Curbow BA, Wingard JR, McDonnell K, Somerfield MR. Can 40 seconds of compassion reduce patient anxiety? J Clin Oncol. 1999;17(10458256):371–379.
    1. Hurny C, Bernhard J, Bacchi M, van Wegberg B, Tomamichel M, Spek U, Coates A, Castiglione M, Goldhirsch A, Senn HJ. The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG) Support Care Cancer. 1993;1(8193882):200–208.
    1. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.
    1. Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM. Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer. 2001;84(11336464):1156–1165.
    1. Bernhard J, Hurny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn HJ, Rudenstam CM. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann Oncol. 1997;8(9358933):825–835.
    1. Bernhard J, Maibach R, Thurlimann B, Sessa C, Aapro MS. Patients’ estimation of overall treatment burden: why not ask the obvious? J Clin Oncol. 2002;20(1):65–72. doi: 10.1200/JCO.20.1.65.
    1. Strull WM, Lo B, Charles G. Do patients want to participate in medical decision making? JAMA. 1984;252(6502860):2990–2994.
    1. Donner A, Klar N. Statistical considerations in the design and analysis of community intervention trials. J Clin Epidemiol. 1996;49(4):435–439. doi: 10.1016/0895-4356(95)00511-0.
    1. Lake S, Kammann E, Klar N, Betensky R. Sample size re-estimation in cluster randomization trials. Stat Med. 2002;21(10):1337–1350. doi: 10.1002/sim.1121.
    1. Allen McDowell JP. From the help desk: It’s all about the sampling. Stata J. 2002;2(Number 2):190–201.
    1. Michael Friendly. SAS Macro Programs: fpower. .
    1. Wright EP, Selby PJ, Crawford M, Gillibrand A, Johnston C, Perren TJ, Rush R, Smith A, Velikova G, Watson K. et al.Feasibility and compliance of automated measurement of quality of life in oncology practice. J Clin Oncol. 2003;21(12525532):374–382.
    1. Bruera E, Sweeney C, Willey J, Palmer JL, Tolley S, Rosales M, Ripamonti C. Breast cancer patient perception of the helpfulness of a prompt sheet versus a general information sheet during outpatient consultation: a randomized, controlled trial. J Pain Symptom Manage. 2003;25(12727038):412–419.
    1. Nayak S, Pradhan JPB, Reddy S, Palmer JL, Zhang T, Bruera E. Cancer patients’ perception of the quality of communication before and after the implementation of a communication strategy in a regional cancer center in India. J Clin Oncol. 2005;23(16034053):4771–4775.
    1. Detmar SB, Aaronson NK. Quality of life assessment in daily clinical oncology practice: a feasibility study. Eur J Cancer. 1998;34(9849476):1181–1186.
    1. Ruland CM, Holte HH, Roislien J, Heaven C, Hamilton GA, Kristiansen J, Sandbaek H, Kvaloy SO, Hasund L, Ellison MC. Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients’ need for symptom management support: a randomized clinical trial. J Am Med Inform Assoc. 2010;17(4):403–410. doi: 10.1136/jamia.2010.005660.
    1. Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O’Fallon JR, Mahoney MR, Heid IM, Bretscher ME, Vaught NL. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;16(9817289):3662–3673.
    1. Maguire P. Improving communication with cancer patients. Eur J Cancer. 1999;35(10711246):2058–2065.
    1. Hall JA, Roter DL, Katz NR. Meta-analysis of correlates of provider behavior in medical encounters. Med Care. 1988;26(7):657–675. doi: 10.1097/00005650-198807000-00002.
    1. McPherson CJ, Higginson IJ, Hearn J. Effective methods of giving information in cancer: a systematic literature review of randomized controlled trials. J Public Health Med. 2001;23(11585196):227–234.
    1. Bruera E, Pituskin E, Calder K, Neumann CM, Hanson J. The addition of an audiocassette recording of a consultation to written recommendations for patients with advanced cancer: A randomized, controlled trial. Cancer. 1999;86(10590386):2420–2425.
    1. Smith TJ. The art of oncology: when the tumor is not the target. Tell it like it is. J Clin Oncol. 2000;18(19):3441–3445.
    1. Stewart MA. Effective physician-patient communication and health outcomes: a review. CMAJ. 1995;152(7728691):1423–1433.
    1. Ford S, Fallowfield L, Lewis S. Doctor-patient interactions in oncology. Soc Sci Med. 1996;42(8771634):1511–1519.
    1. Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist. 2000;5(10964998):302–311.
    1. Bruera E, Sweeney C, Calder K, Palmer L, Benisch-Tolley S. Patient preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol. 2001;19(11387361):2883–2885.
    1. De Lima L, Bennett MI, Murray SA, Hudson P, Doyle D, Bruera E, Granda-Cameron C, Strasser F, Downing J, Wenk R. International Association for Hospice and Palliative Care (IAHPC) List of Essential Practices in Palliative Care. J Pain Palliat Care Pharmacother. 2012;26(2):118–122. doi: 10.3109/15360288.2012.680010.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj